Suppr超能文献

迷幻药伤害减少与整合:临床实践的跨理论模型

Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice.

作者信息

Gorman Ingmar, Nielson Elizabeth M, Molinar Aja, Cassidy Ksenia, Sabbagh Jonathan

机构信息

MAPS Public Benefit Corp, Santa Cruz, CA, United States.

Fluence, Woodstock, NY, United States.

出版信息

Front Psychol. 2021 Mar 15;12:645246. doi: 10.3389/fpsyg.2021.645246. eCollection 2021.

Abstract

Psychedelic Harm Reduction and Integration (PHRI) is a transtheoretical and transdiagnostic clinical approach to working with patients who are using or considering using psychedelics in any context. The ongoing discussion of psychedelics in academic research and mainstream media, coupled with recent law enforcement deprioritization of psychedelics and compassionate use approvals for psychedelic-assisted therapy, make this model exceedingly timely. Given the prevalence of psychedelic use, the therapeutic potential of psychedelics, and the unique cultural and historical context in which psychedelics are placed, it is important that mental health providers have an understanding of the unique motivations, experiences, and needs of people who use them. PHRI incorporates elements of harm reduction psychotherapy and psychedelic-assisted psychotherapy, and can be applied in both brief and ongoing psychotherapy interactions. PHRI represents a shift away from assessment limited to untoward outcomes of psychedelic use and abstinence-based addiction treatment paradigms and toward a stance of compassionate, destigmatizing acceptance of patients' choices. Considerations for assessment, preparation, and working with difficult experiences are presented.

摘要

迷幻药危害减少与整合(PHRI)是一种跨理论和跨诊断的临床方法,用于治疗在任何情况下使用或考虑使用迷幻药的患者。学术研究和主流媒体对迷幻药的持续讨论,再加上最近执法部门对迷幻药的不再优先处理以及迷幻药辅助疗法的同情使用批准,使得这种模式极其及时。鉴于迷幻药使用的普遍性、迷幻药的治疗潜力以及迷幻药所处的独特文化和历史背景,心理健康提供者了解使用迷幻药的人群的独特动机、经历和需求非常重要。PHRI融合了危害减少心理治疗和迷幻药辅助心理治疗的元素,可应用于短期和持续的心理治疗互动中。PHRI代表了一种转变,从仅限于迷幻药使用不良后果的评估和基于禁欲的成瘾治疗范式,转向对患者选择持同情、消除污名化的接受态度。文中还介绍了评估、准备以及应对困难经历的注意事项。

相似文献

1
Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice.
Front Psychol. 2021 Mar 15;12:645246. doi: 10.3389/fpsyg.2021.645246. eCollection 2021.
2
Compassionate use of psychedelics.
Med Health Care Philos. 2020 Sep;23(3):485-496. doi: 10.1007/s11019-020-09958-z.
3
Ethical and legal issues in psychedelic harm reduction and integration therapy.
Harm Reduct J. 2021 Apr 7;18(1):40. doi: 10.1186/s12954-021-00489-1.
4
Psychedelics and Psychotherapy: Cognitive-Behavioral Approaches as Default.
Front Psychol. 2022 May 23;13:873279. doi: 10.3389/fpsyg.2022.873279. eCollection 2022.
5
6
Microdosing psychedelics: Motivations, subjective effects and harm reduction.
Int J Drug Policy. 2020 Jan;75:102600. doi: 10.1016/j.drugpo.2019.11.008. Epub 2019 Nov 25.
7
The Emerging Field of Psychedelic Psychotherapy.
Curr Psychiatry Rep. 2022 Oct;24(10):583-590. doi: 10.1007/s11920-022-01363-y. Epub 2022 Sep 21.
8
Ethical and Practical Considerations for the Use of Psychedelics in Psychiatry.
Psychiatr Serv. 2023 Aug 1;74(8):838-846. doi: 10.1176/appi.ps.20220525. Epub 2023 Mar 29.
9
Safety considerations in the evolving legal landscape of psychedelic-assisted psychotherapy.
Subst Abuse Treat Prev Policy. 2022 May 14;17(1):37. doi: 10.1186/s13011-022-00468-0.
10
Virtual Reality as a Moderator of Psychedelic-Assisted Psychotherapy.
Front Psychol. 2022 Mar 4;13:813746. doi: 10.3389/fpsyg.2022.813746. eCollection 2022.

引用本文的文献

3
Participants' Experience of Psychedelic Integration Groups and Processes: A Qualitative Thematic Analysis.
Psychedelic Med (New Rochelle). 2025 Feb 27;3(1):19-30. doi: 10.1089/psymed.2024.0027. eCollection 2025 Mar.
6
The Afterglow Inventory (AGI): Validation of a new instrument for measuring subacute effects of classic serotonergic psychedelics.
J Psychopharmacol. 2025 May;39(5):474-488. doi: 10.1177/02698811251326937. Epub 2025 Mar 31.
7
Psychedelic iatrogenic structural dissociation: an exploratory hypothesis on dissociative risks in psychedelic use.
Front Psychol. 2025 Mar 4;16:1528253. doi: 10.3389/fpsyg.2025.1528253. eCollection 2025.
8
Protective Behavioral Strategies for Psychedelic Use: A Mini Review of the Evidence.
Psychedelic Med (New Rochelle). 2024 Dec 2;2(4):234-242. doi: 10.1089/psymed.2023.0052. eCollection 2024 Dec.
9
Ayahuasca-assisted meaning reconstruction therapy for grief: a non-randomized clinical trial protocol.
Front Psychiatry. 2025 Jan 7;15:1484736. doi: 10.3389/fpsyt.2024.1484736. eCollection 2024.
10
Cosmology of belonging: The role of community in the therapeutic use of psychedelics.
Palliat Support Care. 2025 Jan 21;23:e27. doi: 10.1017/S1478951524001688.

本文引用的文献

1
Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety.
J Contextual Behav Sci. 2020 Jan;15:39-45. doi: 10.1016/j.jcbs.2019.11.004. Epub 2019 Nov 16.
2
Trends in LSD use among US adults: 2015-2018.
Drug Alcohol Depend. 2020 Jul 1;212:108071. doi: 10.1016/j.drugalcdep.2020.108071. Epub 2020 May 15.
3
Ayahuasca Users in Estonia: Ceremonial Practices, Subjective Long-Term Effects, Mental Health, and Quality of Life.
J Psychoactive Drugs. 2020 Jul-Aug;52(3):255-263. doi: 10.1080/02791072.2020.1748773. Epub 2020 Apr 17.
4
Mystical and Other Alterations in Sense of Self: An Expanded Framework for Studying Nonordinary Experiences.
Perspect Psychol Sci. 2020 May;15(3):669-690. doi: 10.1177/1745691619895047. Epub 2020 Feb 13.
5
Ayahuasca's 'afterglow': improved mindfulness and cognitive flexibility in ayahuasca drinkers.
Psychopharmacology (Berl). 2020 Apr;237(4):1161-1169. doi: 10.1007/s00213-019-05445-3. Epub 2020 Jan 11.
6
Ceremonial "plant medicine" use and its relationship to recreational drug use: an exploratory study.
Addict Res Theory. 2019;27(2):68-75. doi: 10.1080/16066359.2018.1455187. Epub 2018 Mar 30.
7
REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics.
Pharmacol Rev. 2019 Jul;71(3):316-344. doi: 10.1124/pr.118.017160.
8
Replication and extension of a model predicting response to psilocybin.
Psychopharmacology (Berl). 2019 Nov;236(11):3221-3230. doi: 10.1007/s00213-019-05279-z. Epub 2019 Jun 15.
9
Cessation and reduction in alcohol consumption and misuse after psychedelic use.
J Psychopharmacol. 2019 Sep;33(9):1088-1101. doi: 10.1177/0269881119845793. Epub 2019 May 14.
10
A Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy.
Front Psychiatry. 2019 Mar 20;10:138. doi: 10.3389/fpsyt.2019.00138. eCollection 2019.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验